Инкретиновая система и женская репродуктивная функция: распределение рецепторов, молекулярные механизмы и новые терапевтические перспективы

1. Lee J.M., Sharifi M., Oshman L., Griauzde D.H., Chua K.P. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023. JAMA. 2024; 331(23): 2041-43. https://dx.doi.org/10.1001/jama.2024.7112
2. Zhou L., Qu H., Yang L., Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr. Disord. 2023; 23(1): 245. https://dx.doi.org/10.1186/s12902-023-01500-5
3. Papaetis G.S., Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons. Adv. Clin. Exp. Med. 2022; 31(11): 1265-74. https://dx.doi.org/10.17219/acem/151695
4. Austregésilo de Athayde De Hollanda Morais B., Martins Prizão V., de Moura de Souza M., Ximenes Mendes B., Rodrigues Defante M.L., Cosendey Martins O. et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J. Diabetes Complications. 2024; 38(10): 108834. https://dx.doi.org/10.1016/j.jdiacomp.2024.108834
5. Шабатукова Е.В., Щербань Д.А., Кудратова Е.А., Скворцова А.А., Жукова О.В. Современная фармакотерапия синдрома поликистозных яичников. Акушерство и гинекология. 2025; 7: 153-60. https://dx.doi.org/10.18565/aig.2025.83
6. Ye Z.R., Yan C.Q., Liao N., Wen S.H. The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Reprod. Sci. 2023; 30(8): 2349-61. https://dx.doi.org/10.1007/s43032-023-01222-y
7. Salamun V., Jensterle M., Janez A., Vrtacnik-Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur. J. Endocrinol. 2018; 179(1): 1-11. https://dx.doi.org/10.1530/EJE-18-0175
8. Yang Q., Wang F. Successful pregnancy after improving insulin resistance with the glucagon-like peptide-1 analogue in a woman with polycystic ovary syndrome: a case report and review of the literature. Gynecol. Obstet. Invest. 2016; 81(5): 477-80. https://dx.doi.org/10.1159/000446951
9. Барсуков И.А., Тазина Т.В., Фаниев М.В. Многогранность репродуктивных нарушений у пациентов с ожирением: взгляд эндокринолога, акушера-гинеколога и уролога. РМЖ. Мать и дитя. 2024; 7(3): 250-60. https://dx.doi.org/10.32364/2618-8430-2024-7-3-10
10. Kanda R., Hiraike H., Wada-Hiraike O., Ichinose T., Nagasaka K., Sasajima Y. et. al. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer. 2018; 18(1): 657. https://dx.doi.org/10.1186/s12885-018-4570-8
11. Hagemann A.R., Hagemann I.S., Mutch D.G., Devor E.J., Malmrose P.K., Zhang Y. et al. Enhancing progestin therapy with a glucagon-like peptide-1 agonist for the conservative management of endometrial cancer. Cancers (Basel). 2025; 17(4): 598. https://dx.doi.org/10.3390/cancers17040598
12. Wang L., Xu R., Kaelber D.C., Berger N.A. Glucagon-Like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw. Open. 2024; 7(7): e2421305. https://dx.doi.org/10.1001/jamanetworkopen.2024.21305
13. Wang M., Dong T., Lucero M., Pan W., Wang X., Zhou L. et al. Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: a population-based cohort study. Gynecol. Oncol. 2025; 199: 57-63. https://dx.doi.org/10.1016/j.ygyno.2025.06.012
14. Jensterle M., Janez A., Fliers E., DeVries J.H., Vrtacnik-Bokal E., Siegelaar S.E. The role of glucagonlike peptide-1 in reproduction: from physiology to therapeutic perspective. Hum. Reprod. Update. 2019; 25(4): 504-17. https://dx.doi.org/10.1093/humupd/dmz019
15. Athar F., Karmani M., Templeman N.M. Metabolic hormones are integral regulators of female reproductive health and function. Biosci. Rep. 2024; 44(1). https://dx.doi.org/10.1042/BSR20231916
16. Khan D., Ojo O.O., Woodward O.R., Lewis J.E., Sridhar A., Gribble F.M. et. al. Evidence for involvement of GIP and GLP-1 receptors and the Gut-Gonadal axis in regulating female reproductive function in mice. Biomolecules. 2022; 12(12): 1736. https://dx.doi.org/10.3390/biom12121736
17. Zhang Y., Lin Y., Li G., Yuan Y., Wang X., Li N. at. al. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue. Biol. Reprod. 2023; 108(6): 945-59. https://dx.doi.org/10.1093/biolre/ioad032
18. Guo S., Li X., Liu M., Feng M., Wang X., Xue H. et. al. Semaglutide alleviates ovarian oxidative stress and autophagy via the PI3K/AKT/mTOR pathway in mice with polycystic ovary syndrome. Drug. Des. Devel. Ther. 2025; 19: 4297-310. https://dx.doi.org/10.2147/DDDT.S522730
19. Горина К.А., Ходжаева З.С., Белоусов Д.М., Баранов И.И., Гохберг Я.А., Пащенко А.А. Преждевременные роды: прошлые ограничения и новые возможности. Акушерство и гинекология. 2020; 1: 12-9. https://dx.doi.org/10.18565/aig.2020.1.12-119
20. Liu M., Guo S., Li X., Tian Y., Yu Y., Tang L. et.al. Semaglutide alleviates ovary inflammation via the AMPK/SIRT1/NF-κB signaling pathway in polycystic ovary syndrome mice. Drug. Des. Devel. Ther. 2024; 18: 3925-38. https://dx.doi.org/10.2147/DDDT.S484531
21. Sun Z., Li P., Wang X., Lai S., Qiu H., Chen Z. et. al. GLP-1/GLP-1R signaling regulates ovarian PCOS-associated granulosa cells proliferation and antiapoptosis by modification of forkhead box protein O1 phosphorylation sites. Int. J. Endocrinol. 2020; 2020: 1484321. https://dx.doi.org/10.1155/2020/1484321
22. Artunc-Ulkumen B., Pala H.G., Pala E.E., Yavasoglu A., Yigitturk G., Erbas O. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol. Endocrinol. 2014; 31(3):196-201. https://dx.doi.org/10.3109/09513590.2014.975686
23. Wolszczak M., Wołodkiewicz H., Szmit J. The impact of GLP-1 receptor agonists on women’s reproductive health: a review. J. Educ., Health Sport. 2025; 82: 60194. https://dx.doi.org/10.12775/JEHS.2025.82.60194
24. Pathare A., Apostolov A., Lavõgina D., Kask K., Risal S., Ruiz-Durán S. et. al. Impact of glucagon-like peptide-1 receptor (GLP-1R) agonist therapy on the endometrium and embryo: a boon to infertility? Hum. Reprod. 2025; 40. https://dx.doi.org/10.1093/humrep/deaf097.220
25. Salamun V., Lovrecic L., Maver A., Peterlin B., Ban Frangez H., Riemma G. et al. Endometrial transcriptome changes following short-term liraglutide treatment in infertile women with polycystic ovarian syndrome and obesity. Gynecol. Obstet. Invest. 2026; 91(2): 241-50. https://dx.doi.org/10.1159/000547513
26. Wu L., Zhan Y., Wang Y. Semaglutide may ameliorate fibrosis and inhibit epithelial–mesenchymal transition in intrauterine adhesion models. Int. J. Mol. Sci. 2024; 25(11): 6196. https://dx.doi.org/10.3390/ijms25116196
27. Xiong C., Wu J., Ma Y., Li N., Wang X., Li Y. et. al. Effects of glucagon-like peptide-1 receptor agonists on gut microbiota in dehydroepiandrosterone-induced polycystic ovary syndrome mice: compared evaluation of liraglutide and semaglutide intervention. Diabetes Metab. Syndr. Obes. 2024; 17: 865-80. https://dx.doi.org/10.2147/DMSO.S451129
28. Qiao L., Lu C., Zang T., Dzyuba B., Shao J. Maternal GLP-1 receptor activation inhibits fetal growth. Am. J. Physiol. Endocrinol. Metab. 2024; 326(3): E268-76. https://dx.doi.org/10.1152/ajpendo.00361.2023
29. Dumolt J.H., Rosario F.J., Kramer A.C., Horwitz S., Powell T.L., Jansson T. Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clin. Sci. (Lond). 2023; 137(8): 663-78. https://dx.doi.org/10.1042/CS20220890
30. Кан Н.Е., Солдатова Е.Е., Тютюнник В.Л., Борисова А.Г., Тезиков Ю.В., Липатов И.С., Садекова А.А., Алексеев А.А., Красный А.М. Факторы энергетического метаболизма при задержке роста плода. Акушерство и гинекология. 2024; 5: 44-52. https://dx.doi.org/10.18565/aig.2024.9
31. Красный А.М., Кан Н.Е., Борисова А.Г., Солдатова Е.Е., Тютюнник В.Л., Волочаева М.В. Влияние инкретина глюкагоноподобного пептида-1 на фенотипический профиль мононуклеарных клеток при задержке роста плода. Акушерство и гинекология. 2024; 10: 74-81. https://dx.doi.org/10.18565/aig.2024.156
32. Muller D.R.P., Stenvers D.J., Malekzadeh A., Holleman F., Painter R.C., Siegelaar S.E. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front. Endocrinol. 2023; 14: 1215356. https://dx.doi.org/10.3389/fendo.2023.1215356
33. Caruso I., Gioia L.D., Molfetta S.D., Cignarelli A., Palmer S.C., Natale P. et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine. 2023; 64: 102181. https://dx.doi.org/10.1016/j.eclinm.2023.102181
34. Wyckoff J.A., Lapolla A., Asias-Dinh B.D., Barbour L.A., Brown F.M., Catalano P.M. et. al. Preexisting diabetes and pregnancy: an Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. J. Clin. Endocrinol. Metabol. 2025; 110(9): 2405-52. https://dx.doi.org/10.1210/clinem/dgaf288
35. Cesta C.E., Rotem R., Bateman B.T., Chodick G., Cohen J.M., Furu K. et al. Safety of GLP-1 receptor agonists and other secondline antidiabetics in early pregnancy. JAMA Intern. Med. 2024; 184(2): 144-52. https://dx.doi.org/10.1001/jamainternmed.2023.6663
36. Armstrong B.B.S., Servidoni A.C.P., Martin G.C. de C., Machado G.F., Amador W.F.O., Yousif A. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: a systematic review and meta-analysis. J. Gynecol. Obstet. Hum. Reprod. 2025; 54(10): 103046. https://dx.doi.org/10.1016/j.jogoh.2025.103046
37. Parker C.H., Slattery C., Brennan D.J., le Roux C.W. Glucagon-like peptide 1 receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes. Metab. 2025; 27(8): 4102-08. https://dx.doi.org/10.1111/dom.16437
38. Drummond R.F., Seif K.E., Reece E.A. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am. J. Obstet. Gynecol. 2025; 232(1): 17-25. https://dx.doi.org/10.1016/j.ajog.2024.08.024
39. Kolding L., Henriksen J.N., Sædder E.A., Ovesen P.G., Pedersen L.H. Pregnancy outcomes after semaglutide exposure. Basic Clin. Pharmacol. Toxicol. 2025; 136(4): e70021. https://dx.doi.org/10.1111/bcpt.70021
40. Imbroane M.R., LeMoine F., Nau C.T. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am. J. Obstet. Gynecol. 2025; 233(2): 116.e1-e7. https://dx.doi.org/10.1016/j.ajog.2025.01.019
41. Skov K., Mandic I.N., Nyborg K.M. Semaglutide and pregnancy. Int. J. Gynecol. Obstet. 2023; 163(2): 700-1. https://dx.doi.org/10.1002/ijgo.15092
42. Livadas S., Macut D., Bothou C., Kuliczkowska-Płaksej J., Vryonidou A., Bjekic-Macut J. et al. Insulin resistance, androgens, and lipids are gradually improved in an age-dependent manner in lean women with polycystic ovary syndrome: insights from a large Caucasian cohort. Hormones. 2020; 19(4): 531-39. https://dx.doi.org/10.1007/s42000-020-00211-z
43. Alghamdi A., Alsaeddi A., Malki H., Alsaedi A. A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy. Cureus. 2023; 15(9): e44644. https://dx.doi.org/10.7759/cureus.44644
44. Burlina S., Cioccoloni D., Romanello G., Lombardi S. Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes. Acta Diabetol. 2025; 63: 343-5. https://dx.doi.org/10.1007/s00592-025-02601-4
45. Molteni M., Lodigiani S., Teliti M., Rotondi M., Guazzoni V. Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy. Acta Diabetol. 2024; 61(11): 1491-4. https://dx.doi.org/10.1007/s00592-024-02331-z
46. Greco D. Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes. Diabetic Med. 2015; 32(10): e29–30. https://dx.doi.org/10.1111/dme.12726
47. Ivanišević M., Herman M., Horvatiček M., Lovrenčić Vučić M., Đelmiš J. Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report. Gynaecol. Perinatol. 2018; 27(3-4): 70-2.
48. Williams J., Pomeroy N.E., Pop-Busui R., Lash R., Douyon L., Chames M. et al. Case report: exenatide use during pregnancy. Endocrinol. 2009; 19(3): 119-21. https://dx.doi.org/10.1097/TEN.0b013e3181a5875e
49. Doğan G.O., Erbaş O. Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways. Cir. Cir. 2024; 93(1): 35-40. https://dx.doi.org/10.24875/CIRU.23000304
50. Мелкозерова О.А., Мурзин А.В., Третьякова Т.Б., Дерябина Е.Г. Молекулярно-генетические предикторы перинатальных осложнений гестационного сахарного диабета у беременных после применения вспомогательных репродуктивных технологий. РМЖ. Мать и дитя. 2024; 7(1): 4-11 https://dx.doi.org/10.32364/2618-8430-2024-7-1-1
51. Diab H., Fuquay T., Datta P., Bickel U., Thompson J., Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024; 16(17): 2886. https://dx.doi.org/10.3390/nu16172886
52. Min T., Bain S.C. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021; 12(1): 143-57. https://dx.doi.org/10.1007/s13300-020-00981-0
53. Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front. Endocrinol. 2022; 13: 1004044. https://dx.doi.org/10.3389/fendo.2022.1004044
54. Мкртумян А.М., Егшатян Л.В. Отечественный твинкретин Седжаро: один препарат – несколько мишеней. Эффективная фармакотерапия. 2025; 21(46): 30-6. https://dx.doi.org/10.33978/2307-3586-2025-21-46-30-36
55. Coskun T., Urva S., Roell W.C., Qu H., Loghin C., Moyers J.S. et. al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022; 34(9): 1234-47.e9. https://dx.doi.org/10.1016/j.cmet.2022.07.013
56. Jastreboff A.M., Kaplan L.M., Frías J.P., Wu Q., Du Y., Gurbuz S. et. al. Triple–hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N. Engl. J. Med. 2023; 389(6): 514-26. https://dx.doi.org/10.1056/NEJMoa2301972
57. Bomholt A.B., Johansen C.D., Christensen J.B., Kjeldsen S.A.S., Galsgaard K.D., Winther-Sørensen M. et. al. Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression. Commun. Biol. 2022; 5(1): 1278. https://dx.doi.org/10.1038/s42003-022-04242-7
58. Cilvik S.N., Wesolowski S.R., Anthony R.V., Brown L.D., Rozance P.J. Late gestation fetal hyperglucagonaemia impairs placental function and results in diminished fetal protein accretion and decreased fetal growth. J. Physiol. 2021; 599(13): 3403-27. https://dx.doi.org/10.1113/JP281288
59. Şentürk Ş., Hatirnaz S., Kanat-Pektaş M. Serum preptin and amylin levels with respect to body mass index in polycystic ovary syndrome patients. Med. Sci. Monit. 2018; 24: 7517-23. https://dx.doi.org/10.12659/MSM.912957

Поступила 15.12.2025

Принята в печать 05.06.2026